The challenges that trade secrets pose to IP stakeholders
For companies, policy makers and service providers, the growing importance of know-how as a quantifiable asset presents dangers and opportunities
For companies, policy makers and service providers, the growing importance of know-how as a quantifiable asset presents dangers and opportunities
President can now pick out foreign entities and subject them to a series of sanctions
The onus of identifying known substances in pharmaceutical patent applications is on the Indian Patent Office, according to a new ruling, which provides fresh clarity for prospective applicants.
The Asia-Pacific region’s premier event about the business of IP will take place in the Japanese capital from 31 October to 2 November
10 August 2022
Chi Su is under suspicion of “serious violations of discipline and law”, although there is no detail of the specific charges he may be facing
10 August 2022
Paul Michel, former Chief Judge of the US Court of Appeals for the Federal Circuit, and ex-USPTO Director David Kappos urge Congress to embrace legislation designed to repair patent eligibility law which they believe the US Supreme Court has distorted
06 August 2022
Despite the increasing attraction of the London courts, the real FRAND focus in Europe is likely to be on EU action which is promised by the end of the year
05 August 2022
The Patent Eligibility Restoration Act of 2022 effectively overturns Supreme Court precedent and provides greater clarity on eligibility but some believe it may require further work
03 August 2022
While most observers welcome a revisit, many believe that only the Supreme Court or Congress can deliver significant levels of certainty on eligibility
02 August 2022
In an exclusive interview, Tim Moss talks through the five years he spent leading the agency and provides an update on its current study of SEP/FRAND policy issues
02 August 2022
Domestic entities lead the charge, with authorities also keen to encourage further international filings
02 August 2022
Filing in Waco now seems a real gamble, as a deep dive on Docket Navigator reveals that most of Alan Albright’s colleagues have handled a relatively low number of cases
01 August 2022
Legislators put pharma companies under the microscope and blame a law signed by President Trump in 2017 for patent-based payment mitigation
01 August 2022
Unlock unlimited access to all IAM content